Xuanzhubio-b
2575
Rank in Stocks
#11542
Xuanzhu Biopharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the... Xuanzhu Biopharmaceutical Co., Ltd. is a Chinese enterprise dedicated to the research, production, and commercialization of both small-molecule chemical compounds and large-molecule biopharmaceuticals. The company's primary drug candidates include Core- KBP-3571, developed for treating duodenal ulcers; XZP-3287, a CDK4/6 inhibitor aimed at advanced HR+/HER2 breast cancer; and XZP-3621, intended as a first-line therapy for patients suffering from anaplastic lymphoma kinase-positive (ALK+) advanced non-small-cell lung cancer. Its development pipeline further encompasses KM501, a pioneering HER2/HER2 bispecific antibody drug conjugate currently in Phase I clinical trials, alongside KM602, another anti-tumor agent also undergoing Phase I evaluation. Other investigational assets include XZP-7797, a selective and brain-penetrating poly ADP-ribose polymerase 1 (PARP1) inhibitor; XZP-6924, which targets ubiquitin-specific protease 1 (USP1); XZB-0004, an oral small molecule anexelekto inhibitor; and XZP-6877, a DNA-dependent protein kinase inhibitor. The portfolio also features NG-350A, a next-generation oncolytic viral therapy; XZP-5610, a non-steroidal farnesoid X receptor; and XZP-6019, a first-in-class ketohexokinase (KHK) inhibitor. Founded in 2008 and headquartered in Beijing, China, Xuanzhu Biopharmaceutical Co., Ltd. operates as a subsidiary of Sihuan Pharm.
Share Price
$1.07
Last synced: 2026-11-10
Market Cap
$555.11M
Change (1 day)
1.51%
Change (1 year)
-86.97%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Xuanzhubio-b (2575)
Category
Healthcare
EPS for Xuanzhubio-b (2575)
EPS as of June 2026 TTM: $-0.06
According to Xuanzhubio-b's latest financial reports, its current EPS (TTM) is $-0.06. At the end of 2025 the company had an EPS of $-0.07, an increase over its 2024 EPS of $-0.15.
EPS history for Xuanzhubio-b from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.06 | -12.57% |
| 2025 | $-0.07 | -56.16% |
| 2024 | $-0.15 | 82.20% |
| 2023 | $-0.08 | -44.29% |
| 2022 | $-0.15 | -20.30% |
| 2021 | $-0.18 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $6.50 | -10,723.20% |
DE
|
|
| $6.08 | -10,030.72% |
DE
|
|
| $1.55 | -2,633.66% |
JP
|
|
| $3.66 | -6,080.39% |
CH
|
|
| $0.45 | -835.29% |
IL
|
Questions about Xuanzhubio-b's earnings per share (EPS)
What is Xuanzhubio-b's earnings per share (EPS)?
Xuanzhubio-b's earnings per share (EPS) over the last twelve months is $-0.06, as of Jun 2026.
What was Xuanzhubio-b's earnings per share (EPS) in 2025?
In 2025, Xuanzhubio-b's earnings per share (EPS) was $-0.07, compared with $-0.15 in 2024.
How has Xuanzhubio-b's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Xuanzhubio-b's earnings per share (EPS) was highest in 2020 (0.00) and lowest in 2021 ($-0.18).
How does Xuanzhubio-b's earnings per share (EPS) compare with similar companies?
Xuanzhubio-b's earnings per share (EPS) ($-0.06) is lower than that of all 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.50.